'Fine tuning' HIV therapy. Report on the 9th Conference on Retroviruses and Opportunistic Infections.
Linde
Michael
M
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D015224:Dideoxynucleosides / Q000009:adverse effects; D004334:Drug Administration Schedule; D004342:Drug Hypersensitivity; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008060:Lipodystrophy / Q000139:chemically induced; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects; D014481:United States / Q000453:epidemiology; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir